In the early 2000s, it was recognized that tumour cells with defective homologous recombination DNA repair pathways, such as BRCA1/2-deficient cancer cells, are highly sensitive to the inhibition of PARP activity (Bryant et al., 2005; Farmer et al., 2005). The gene discussed is PARP1; the disease is cancer.